Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Harvard Business School
Merck
McKinsey
AstraZeneca

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

TAGRISSO Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Tagrisso patents expire, and what generic alternatives are available?

Tagrisso is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and fifteen patent family members in forty-one countries.

The generic ingredient in TAGRISSO is osimertinib mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the osimertinib mesylate profile page.

Summary for TAGRISSO
Drug patent expirations by year for TAGRISSO
Drug Prices for TAGRISSO

See drug prices for TAGRISSO

Generic Entry Opportunity Date for TAGRISSO
Generic Entry Date for TAGRISSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAGRISSO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
TakedaPhase 1
Collin BlakelyPhase 1
AstraZenecaPhase 3

See all TAGRISSO clinical trials

Synonyms for TAGRISSO
1421373-65-0
1421373-66-1
1610419-47-0
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, methanesulfonate (1:1)
3C06JJ0Z2O
4CA-0243
ABP001123
AC-29019
AC-29022
AK170511
AK198680
AKOS025290756
AKOS026673944
AOB6268
AS-16943
AZD 9291
AZD 9291 mesylate
AZD-9291
AZD-9291 (Mesylate)
AZD-9291 mesylate
AZD-9291 mesylate pound Osimertinib Mereletinib)
AZD9291
AZD9291 mesylate
AZD9291 Ms salt, Osimertinib Ms salt; Mereletinib Ms salt
BC600811
BCP08626
BCP09934
BDBM50029668
C28H33N7O2
CHEBI:90943
CHEBI:90948
CHEMBL3353410
CHEMBL3545063
CS-2018
D10766
DB09330
DS-9913
DUYJMQONPNNFPI-UHFFFAOYSA-N
EX-A1577
EX-A314
FT-0696828
FT-0699962
GTPL7719
HMS3653E10
HY-15772
HY-15772A
KB-330516
KS-000007ZW
KS-00000SU8
Mereletinib
mereletinib (obsolete INN)
Mereletinib [INN]
Mereletinib mesylate
Mereletinib pound AZD-9291 Osimertinib pound(c)
MolPort-035-395-886
MolPort-044-560-736
N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)acrylamide
N-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide methanesulfonate
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
NCGC00378622-10
osimertinib
Osimertinib [USAN]
osimertinib mesilate
Osimertinib mesilate (JAN)
Osimertinib mesylate
Osimertinib mesylate (USAN)
Osimertinib mesylate [USAN]
osimertinib methanesulfonate
osimertinib monomesylate
osimertinibum
QC-11454
RDL94R2A16
s7297
SB22952
SB22953
SC-94470
SCHEMBL14660911
SCHEMBL14661152
SW219863-1
Tagrisso (TN)
Tube720
UNII-3C06JJ0Z2O
UNII-RDL94R2A16
X3507
ZINC98023177

US Patents and Regulatory Information for TAGRISSO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
Baxter
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.